Archive for Society

Jeff Koobs New Book Criticizes Ad-Centric Society


COLUMBIA, S.C. (PRWEB) May 27, 2015

Healthy eating and dieting are often at the forefront of the news and media. Author and psychologist Jeff Koob also emphasizes the importance of a healthy diet, but in regards to the U.S. and society’s consumption of advertising, not food. Furthermore, he believes that the country’s diet as a whole is suffering because of one junk food: propaganda.

Koob hopes to lift the veil on propaganda with his new book, “Ad Nauseam: How Advertising and Public Relations Changed Everything” (published by iUniverse), which discusses the propaganda-driven society of today, its potential downfalls, the evils of social engineering and the solutions he sees.

“Most people can’t recognize the techniques of propaganda and don’t think they are influenced by it,” Koob says.

Koob uses a “psycho-linguistic” approach to examine society and the presence of propaganda today. He begins by looking at the history of propaganda and advertising in an attempt to answer the question: “How did we get here?” He then examines what he refers to as “psycho-technologies” in order to see the extent of their influence on the shaping of modern life.

Throughout “Ad Nauseam,” readers will learn about the various ways in which advertising and propaganda has shaped society, both culturally and socially. Koob hopes his book will help readers realize propaganda’s grasp over their lives so they can break free from it.

“Ad Nauseam”

By Jeff Koob

Softcover | 5 x 8 in | 196 pages | ISBN 9781491758915

E-Book | 196 pages | ISBN 9781491758908

Available at Amazon and Barnes & Noble

About the Author

Jeff Koob earned his bachelor’s degree in English at The Citadel, served for four years in the U.S. Army and then earned a master’s degree in psychology at the University of West Georgia. He worked as a public sector psychologist for over 30 years. He served in Jamaica as a Peace Corps volunteer and served as a Red Cross Disaster Mental Health Volunteer at Ground Zero in New York City following the attack on the World Trade Center. He lives with his wife in Columbia, South Carolina.

iUniverse, an Author Solutions, LLC, self-publishing imprint, is the leading book marketing, editorial services, and supported self-publishing provider. iUniverse has a strategic alliance with Indigo Books & Music, Inc. in Canada, and titles accepted into the iUniverse Rising Star program are featured in a special collection on BarnesandNoble.com. iUniverse recognizes excellence in book publishing through the Star, Reader’s Choice, Rising Star and Editor’s Choice designations—self-publishing’s only such awards program. Headquartered in Bloomington, Indiana, iUniverse also operates offices in Indianapolis. For more information or to publish a book, please visit iuniverse.com or call 1-800-AUTHORS. For the latest, follow @iuniversebooks on Twitter.







National Multiple Sclerosis Society Invests $28 Million in New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever


NEW YORK, NY (PRWEB) April 08, 2015

The National Multiple Sclerosis Society has committed $ 28 million to support an expected 84 new MS research projects and training awards. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost, and ending the disease forever – for every single person with MS.

This financial commitment is the latest in the Society’s relentless research efforts to move us closer to a world free of MS, and part of a projected investment of over $ 52 million in 2015 alone to support 380 new and ongoing studies around the world. So that no opportunity is wasted, the Society pursues all promising paths, while focusing on priority areas including progressive MS, nervous system repair, gene/environmental risk factors and wellness and lifestyle.

Just a few of the new cutting-edge research projects include a University of California, San Francisco-led consortium focusing on a comprehensive analysis of the gut microbiome to develop probiotic strategies for stopping progressive MS; a pilot trial at Johns Hopkins University exploring the tolerability of a diet that intermittently restricts calorie intake as a treatment for disease activity in people with MS; pre-clinical studies by a commercial firm (Bionure) to test the potential of a compound to protect the nervous system and stimulate repair of nerve-insulating myelin; and a new collaborative center at Oregon Health & Science University to research patient-centered wellness programs to improve the daily life of people with MS.

“These innovative new projects add to the Society’s comprehensive efforts to stop MS, restore function and end MS forever,” notes Bruce Bebo, PhD, National MS Society’s Executive Vice President, Research. “While we fund more research than any other MS organization in the world, we also convene and empower the research community toward breakthroughs that can help people with MS live their best lives now.”

Multiple sclerosis interrupts the flow of information within the brain and between the brain and the body. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. Worldwide, over 2.3 million people live with the unpredictable challenges of multiple sclerosis.

“MS research is a top National MS Society priority, with increasing annual investments to drive solutions for every person with MS,” says Cynthia Zagieboylo, President and CEO of the Society. “We fund the entire research spectrum, propelling novel ideas into the lab, translating breakthroughs into clinical trials, and moving success in clinical trials into new treatments for people living with MS.”

To find the best research with the most promise, the National MS Society relies on more than 130 world-class scientists who volunteer their time to carefully evaluate hundreds of proposals every year. This rigorous evaluation process assures that Society funds fuel research that delivers results in the shortest time possible.

There are FDA-approved therapies that can impact the underlying disease course in people with the more common forms of MS. However, none of these can stop progression or reverse the damage to restore function. National MS Society-funded research paved the way for existing therapies – none of which existed just several decades ago – and continues to be a driving force of MS research.

About Multiple Sclerosis

Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million worldwide.

About the National Multiple Sclerosis Society

The Society mobilizes people and resources to drive research for a cure and to address the challenges of everyone affected by MS. To fulfill this mission, the Society funds cutting-edge research, drives change through advocacy, facilitates professional education, collaborates with MS organizations around the world, and provides programs and services designed to help people with MS and their families move their lives forward. To move us closer to creating a world free of MS, last year alone, the Society invested $ 50.2 million to support more than 380 new and ongoing research projects around the world while providing program services to over one million people. Join the movement at nationalMSsociety.org.







New Study on BioCell Collagen Published in the Journal of the International Society of Sports Nutrition (JISSN)


Newport Beach, CA (PRWEB) February 23, 2015

BioCell Technology announced today the publication of a new clinical study on BioCell Collagen®. The study, now indexed on PubMed, describes the potential of BioCell Collagen® for protecting the connective tissue of the musculoskeletal system and enhancing recovery from intense exercise. The randomized, double blind, placebo-controlled study was carried out by investigators at the Center for Applied Health Sciences (CAHS) who presented data in June at the 2014 International Society of Sports Nutrition (ISSN) Conference in Clearwater Beach, Florida, USA.

Earlier clinical studies of BioCell Collagen® have substantiated its safety and efficacy in promoting joint health and skin beauty. As these studies provide evidence that the patented healthy aging ingredient supports various connective tissues throughout the body, this proof-of-concept study was conducted to investigate whether daily intake of BioCell Collagen® for six weeks could protect skeletal muscle connective tissue following an intense exercise challenge, and also enhance recovery. Data from the study showed that BioCell Collagen® attenuated deleterious changes in muscle tissue damage and inflammatory biomarkers including creatine kinase, lactate dehydrogenase, and C-reactive protein. In addition, subjects who took BioCell Collagen® appeared to show a more robust “repeated bout effect” as compared to placebo, suggesting augmented tissue recovery and remodeling.    

“Extending its market-leading position as a key joint and skin health ingredient, this new clinical study in recreationally active healthy subjects provides intriguing dataset suggesting that this patented, research-backed dietary supplement has promising new applications in sports nutrition” says Suhail Ishaq, president of BioCell Technology, “This opens up a new category in sports nutrition regarding connective tissue protection and recovery from post-workout soreness and limiting repetitive, overuse related injuries.”

The details of the abstract are published on the JISSN website:

http://www.jissn.com/content/11/S1/P48

About BioCell Collagen®:

BioCell Collagen® is a science based clinically substantiated dietary ingredient that promotes active joints, younger looking skin, and healthy connective tissues. Unlike other collagen and hyaluronic acid ingredients on the market, BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II, chondroitin sulfate, and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials including safety, efficacy, and bioavailability. BioCell Collagen® is a registered trademark of BioCell Technology, LLC (Protected by US and International Patents ). The BioCell Collagen® logo of authenticity is proudly displayed on the labels of finished products that contain BioCell Collagen®. For more information and a directory of where to buy products made with BioCell Collagen®, visit http://www.BioCellCollagen.com.

About BioCell Technology:

BioCell Technology LLC, is in the business of researching, developing, branding, and distributing innovative, science based raw material ingredients that have applications in health and beauty. The company is headquartered in Newport Beach, California USA and operates facilities in Anaheim, California, and Elmshorn, Germany. The company’s executive management team is composed of industry veterans and scientists with decades of experience. Founded in 1997, the company’s goal is to provide non-invasive, economically feasible, long-term solutions that improve quality of life for people all over the globe. As a steward of quality and integrity, BioCell Technology believes that licensing is the best way to ensure the quality, safety, and efficacy of the innovative finished products that contain their branded ingredients in the market. The company’s products are rooted in quality and science and were developed with sustainability in mind. The company does not sell finished products, but rather licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. Each of the branded ingredients have a trademarked logo of authenticity that is proudly displayed on the labels of finished products licensed by BioCell Technology and marketed by leading consumer packaged goods companies under their own brand names or formulas. For more information visit http://www.BioCellTechnology.com.







Related Workout Press Releases

Society for Vascular Medicine Remedies Inaccuracies in New York Times Medicare Article

Deerfield, IL (PRWEB) February 03, 2015

The Society for Vascular Medicine (http://www.vascularmed.org) read with disappointment the New York Times article, “Medicare Payments Surge for Stents to Unblock Blood Vessels in Limbs,” noting a series of inaccuracies that limit the discussion of this very important topic.

First, through the Choosing Wisely initiative (http://www.choosingwisely.org), the Society for Vascular Medicine does not warn that people typically do not need invasive treatment for peripheral artery disease (PAD). Our recommendation states, “[providers should] Refrain from percutaneous or surgical revascularization of peripheral artery stenosis in patients without claudication or critical limb ischemia,” warning against inappropriate use in patients who do not have leg symptoms.

Second, the article decries the surge in vascular procedures, focusing on peripheral artery interventions. However, as the figure in the article clearly shows, artery interventions have been relatively stable since 2006. As noted in the figure, vein interventions have more than doubled over this time period, but warrant scant attention in this article.

Third, the article underestimates significantly the prevalence of PAD in the United States. The best estimates suggests that 1 in 5 men and 1 in 6 women has peripheral artery disease in the Medicare population (patients 65 years or older) (http://www.ncbi.nlm.nih.gov/pubmed/14709362). This misconception prevents physicians and patients from getting life saving care: patients with PAD have a significantly increased risk of cardiovascular death.

Fourth, and perhaps most importantly, the article notes twice that most PAD patients can be treated with exercise alone. Unfortunately, despite extensive clinical evidence that exercise training improves leg symptoms for patients with PAD and is cost effective compared to intervention, Medicare does not cover supervised exercise programs for PAD as it does for heart and lung disease. The prescription for exercise without supervision has been shown to fail time and again. Unfortunately, because of the lack of Medicare coverage for supervised exercise therapy, most PAD patients do not have access to the safest and most cost effective therapies for this disease. The failure of Medicare to pay for inexpensive, effective exercise therapy, while being willing to pay for expensive interventional therapy, warrants further discussion.

The Society for Vascular Medicine strongly endorses the appropriate use of therapies to improve the quality and length of life for patients with vascular disease. We decry inappropriate use of any therapy and have an ongoing commitment to improving the lives of our patients, as well as better understanding of vascular disease. We believe that there is both overuse and underuse of medical and invasive therapies, but the misinterpretation of information only hinders progress towards improving the lives of our patients.

For more information contact SVM Executive Director Lee Ann Clark at lclark(at)vascularmed(dot)org or call 847-480-2961, Ext. 220.

The Society for Vascular Medicine is a professional organization founded in 1989 to improve the integration of vascular biological advances into medical practice, and to maintain high standards of clinical vascular medicine. The Society is distinguished by its emphasis on clinical approaches to vascular disorders. Learn more at http://www.vascularmed.org.







More Exercise Program Press Releases

National Anti-Vivisection Society and International Foundation for Ethical Research Announce New Research Grants for Promising Young Investigators

Chicago, IL (PRWEB) November 11, 2014

The National Anti-Vivisection Society (NAVS) and the International Foundation for Ethical Research (IFER) are pleased to announce three first-time recipients of IFER Graduate Fellowships as part of the 2014-2015 grant cycle. By funding early career researchers with an interest in developing innovative alternatives to animal testing, NAVS and IFER hope to seed the scientific field with talented individuals prepared to integrate scientific discovery with ethics and respect for animals.

Recipients of IFER Graduate Fellowships, selected by IFER’s Scientific Advisory Board, have the potential to positively change the course of science by working to promote the advancement of humane methodologies that can spare animal suffering.

The investigators who are receiving first-time IFER Graduate Fellowships for 2014-2015 are:

Bryan Hassell, a Ph.D. candidate working in Dr. Donald Ingber’s laboratory at the Wyss Institute for Biologically Inspired Engineering at Harvard University, has received funding for his project, “Human Cancer-on-a-Chip as a Replacement for Animal Testing.” Bryan seeks to develop an organ-on-a-chip platform to determine how lung cancer cells respond to chemotherapy depending on their organ-specific microenvironment, as well as to identify new anticancer therapies. Bryan’s physics and engineering background, in combination with the extensive biological training that he is receiving in the Ingber lab, will allow him to take a multidisciplinary approach toward developing an innovative model that has the potential to replace the use of animals in cancer research.

Erica Schlesinger, a Ph.D. student at the University of California San Francisco working in Dr. Tejal Desai’s lab, received support for her project, “In-vitro 3D Flow Through System for Improved Intestinal Permeability Model.” Erica aims to develop a model in which human intestinal cells are grown on a tubular scaffold to better mimic the microenvironment of the intestine. Using this approach, experimental drugs can be flowed through the system, enabling drug absorption to be assessed. This new model has the potential to improve upon existing in vitro approaches to study drug absorption while reducing the need for more complex animal experimentation.

Sun Nee Tan, a Ph.D. candidate in the Graduate Program in Neuroscience at the University of British Columbia under the mentorship of Dr. Martin McKeown, will be using state-of-the-art brain imaging techniques on human subjects for her project, “Structural and Functional Neuroplasticity of Parkinson’s Disease Following a Sensori-Motor Contingent Musical Walking Intervention (Ambulosono).” Her study will determine the effectiveness of a music-contingent walking exercise program as an intervention for Parkinson’s disease subjects. Neuroscience studies traditionally rely heavily on animal models, despite their limited translatability to human populations; therefore the use of imaging techniques on human subjects to study neuroplasticity may replace conventional research which uses animal testing for this purpose.

IFER Graduate Fellowships are awarded annually in amounts up to $ 15,000 to early career scientists who are developing alternatives to the use of animals in product testing, biomedical research and education. Fellowships are renewable for up to three years. More information on the IFER Graduate Fellowship Program can be found at http://www.ifer.org/fellowships.php.

ABOUT THE NATIONAL ANTI-VIVISECTION SOCIETY

Founded in 1929, the National Anti-Vivisection Society (NAVS) promotes greater compassion, respect and justice for animals through educational and advocacy programs based on respected ethical, scientific and legal theory. NAVS works to increase public awareness about animal testing and experimentation, to promote positive solutions that advance science, to support the development of alternatives to the use of animals, and to effect changes that will help end the unnecessary suffering of laboratory animals. For more information, visit http://www.navs.org.

ABOUT THE INTERNATIONAL FOUNDATION FOR ETHICAL RESEARCH

Founded in 1985, the International Foundation for Ethical Research (IFER) supports the development, validation and implementation of innovative scientific methodologies that advance science and replace the use of animals in research, testing and education. IFER is funded primarily by a grant from the National Anti-Vivisection Society.







Related Exercise Program Press Releases